New technology and news

Good Article Sharing

Macromolecular Biopharmaceutical Research*

Macromolecular Biopharmaceutical Research*

Chengdu Tianfu International Biocity was awarded the license and recognized Changrui Biotech as the "public technology platform for carrier drug development and macromolecular biodrug research" in Biocity.

2023-02-02

Changrui Biologics - a public technical service platform for vector drug development and macromolecular biopharmaceutical research

Changrui Biologics - a public technical service platform for vector drug development and macromolecular biopharmaceutical research

On March 29, 2022, Changrui Biotechnology (Chengdu) Co., Ltd. (hereinafter referred to as "Changrui Biotechnology") was awarded the license by Chengdu Tianfu International Biocity, and recognized Changrui Biotechnology as the "public technology platform for carrier drug development and macromolecule biodrug research" in Biocity.

2023-02-02

Changrui Biotech participated in the 2022 college campus job fair

Changrui Biotech participated in the 2022 college campus job fair

On June 2, 2022, invited by the Administrative Committee of Chengdu Tianfu International Biocity, Changrui Biotech participated in the "Chengdu Tianfu International Biocity 2022 College Campus Special Job Fair" held at Southwest University for Nationalities.

2023-02-02

Changrui Biotech participated in the signing ceremony of Chengdu Tianfu International Biocity with a total investment of more than 11 billion yuan - 2022 circle building strong chain project

Changrui Biotech participated in the signing ceremony of Chengdu Tianfu International Biocity with a total investment of more than 11 billion yuan - 2022 circle building strong chain project

On June 10, 2022, Chengdu Tianfu International Biocity held a centralized signing ceremony for the "2022 Building a Circle and Strong Chain" project, and 14 projects were signed at the event site, with a total investment of more than 11 billion yuan.

2023-02-02

2021 Annual Drug Evaluation Report Released - These issues are worth paying attention to

2021 Annual Drug Evaluation Report Released - These issues are worth paying attention to

On June 1, 2022, the State Food and Drug Administration issued the 2021 Annual Drug Evaluation Report (hereinafter referred to as the "Report"). The "Report" shows that China's drug review work in 2021 has achieved outstanding results, including the review of 47 innovative drugs throughout the year, setting a new record high; The overall time-bound completion rate increased to 98.93% throughout the year, and the time-bound completion rate of many projects made historic breakthroughs, including a number of new coronavirus vaccines, therapeutic drugs and innovative drugs, new drugs urgently needed overseas in clinical practice, and the launch of drugs for children.

2023-02-02

CDE issued three guiding principles, including the Technical Guidelines for Pharmaceutical Research and Evaluation of In Vivo Gene Therapy Products (Trial).

CDE issued three guiding principles, including the Technical Guidelines for Pharmaceutical Research and Evaluation of In Vivo Gene Therapy Products (Trial).

On May 31, 2022, the Center for Drug Evaluation (CDE) of the National Medical Products Administration issued three pharmaceutical guidelines: "Technical Guidelines for Pharmaceutical Research and Evaluation of In Vitro Gene Modification Systems (Trial)", "Technical Guidelines for Pharmaceutical Research and Evaluation of Immune Cell Therapy Products (Trial)", and "Technical Guidelines for Pharmaceutical Research and Evaluation of In Vivo Gene Therapy Products (Trial)", all of which came into force on the date of promulgation (May 26, 2022).

2023-02-02

< 12 > proceed page

Macromolecular Biopharmaceutical Research*

2023-02-02

Changrui Biologics - a public technical service platform for vector drug development and macromolecular biopharmaceutical research

2023-02-02

Changrui Biotech participated in the 2022 college campus job fair

2023-02-02

Changrui Biotech participated in the signing ceremony of Chengdu Tianfu International Biocity with a total investment of more than 11 billion yuan - 2022 circle building strong chain project

2023-02-02

2021 Annual Drug Evaluation Report Released - These issues are worth paying attention to

2023-02-02

CDE issued three guiding principles, including the Technical Guidelines for Pharmaceutical Research and Evaluation of In Vivo Gene Therapy Products (Trial).

2023-02-02